BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).

Expected upcoming significant milestones for remainder of 2016:

• Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3 2016
• Second Phase 2a immuno-oncology study in pancreatic cancer, under collaboration with MD Anderson Cancer Center, expected to commence by end of 2016
• Full set of data from Phase 2a study for BL-8040 in r/r AML to be presented at the Society of Hematologic Oncology (SOHO) annual meeting, September 7-10, 2016, in Houston, Texas
• Partial results from Phase 2 study for BL-8040 in stem-cell mobilization for allogeneic transplantation expected by end of 2016
• Regulatory submission for BL-7010 clinical efficacy study, for marketing purposes as food supplement
• Expansion of commercial rollout of BL-5010 by Omega to additional countries and development of 2nd OTC indication for the product

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Mohawk Industries (MHK) Tops Q1 EPS by 19c
• AptarGroup (ATR) Tops Q1 EPS by 11c